Lessons from a Pandemic: Maintaining Compliant GxP Surveillance Programs and Stable Pharmaceutical Supply

References

1. 1.↵
   1. Azar A. M. II..

   Determination that a Public Health Emergency Exists, 2020. U.S. Department of Health and Human Services Public Health Emergency Web site. https://www.phe.gov/emergency/news/healthactions/phe/Pages/2019-nCoV.aspx (accessed September 28, 2020).
2. 2.↵
   Guidance for Industry -Planning for the Effects of High Absenteeism to Ensure Availability of Medically Necessary Drug Products. FDA CDER, 2011. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/planning-effects-high-absenteeism-ensure-availability-medically-necessary-drug-products-0.
3. 3.↵
   Medicines and Healthcare products Regulatory Agency. MHRA Regulatory Flexibilities Resulting from Coronavirus (COVID-19), 2020. GOV.UK Web site. https://www.gov.uk/guidance/mhra-regulatory-flexibilities-resulting-from-coronavirus-covid-19 (accessed September 28, 2020).
4. 4.↵
   Drug Shortages. FDA Website, 2020. https://www.fda.gov/drugs/drug-safety-and-availability/drug-shortages (accessed October 2, 2020).
5. 5.↵
   1. Zhang D

   , FDA data shows numerous drugs in shortage, including a leading antidepressant. USA TODAY [Online]. June 10, 2020. https://www.usatoday.com/story/news/2020/06/10/coronavirus-and-fda-drug-shortage-list/5330491002/ (accessed October 2, 2020).
6. 6.↵
   1. Cundell T.,
   2. Guilfoyle D.,
   3. Kreil T. R.,
   4. Sawant A.

   Controls to Minimize Disruption of the Pharmaceutical Supply Chain during the COVID-19 Pandemic. PDA J. Pharm. Sci. Technol. [Online] 2020, 74 (4), 468–494. https://journal.pda.org/content/74/4/468 (accessed September 28, 2020).

   OpenUrlAbstract/FREE Full Text
7. 7.↵
   1. Rönninger S.,
   2. Schmitt S.,
   3. Rangavajhula V.,
   4. Hough E.,
   5. Lyda J.

   Considerations on Auditing and GxP Requirements along the Product Lifecycle. PDA J. Pharm. Sci. Technol. 2012, 66 (5), 396–402.

   OpenUrlAbstract/FREE Full Text
8. 8.↵
   Parenteral Drug Association Inc. PDA Standard 001-2020, Enhanced Purchasing Controls to Support the Bio-Pharmaceutical, Pharmaceutical, Medical Devices and Combination Products Industries; Bethesda, MD, 2020.
9. 9.↵
   1. Coleman L.

   Making Remote Work. Quality Progress 2020, 53 (9), 16–23.

   OpenUrl
10. 10.↵
    1. Robinson J.

    Considerations for Supply Chains in the Face of COVID-19. Quality Progress 2020, 53 (7), 14–19.

    OpenUrl
11. 11.↵
    1. Fidler D. P.

    Vaccine Nationalism's Politics. Science 2020, 369 (6505), 749.

    OpenUrlAbstract/FREE Full Text
12. 12.↵
    Battling Back. Facing Hard Times, Manufacturers Find Ways to Withstand COVID-19 Setbacks. Quality Progress.2020, 53 (9), 8–9.

    OpenUrl